NFKB1 and metabolic disease: Recent preclinical studies have further expanded the repertoire for the use of DPP4 inhibitors in the treatment of other metabolic diseases and their consequent complications (34), which may block the signaling pathway of DPP4 with NFκB and matrix metallopeptidase 9 in these patients (11, 34).